Abstract
This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.
MeSH terms
-
Ablation Techniques
-
Ascites / radiotherapy
-
Bone Neoplasms / complications
-
Bone Neoplasms / secondary
-
Chemotherapy, Adjuvant
-
Documentation
-
Female
-
Follow-Up Studies
-
Humans
-
Hyperthyroidism / radiotherapy
-
Infection Control
-
Lymphoma, Non-Hodgkin / radiotherapy
-
Ovarian Neoplasms / radiotherapy
-
Pain / etiology
-
Pain / radiotherapy
-
Patient Education as Topic
-
Pleural Effusion / radiotherapy
-
Polycythemia Vera / complications
-
Polycythemia Vera / radiotherapy
-
Postoperative Period
-
Quality Control
-
Radiation Oncology / standards*
-
Radioimmunotherapy
-
Radiopharmaceuticals / administration & dosage
-
Radiopharmaceuticals / adverse effects
-
Radiopharmaceuticals / therapeutic use*
-
Radiotherapy / adverse effects
-
Radiotherapy / standards*
-
Safety
-
Societies, Medical*
-
Thrombocytosis / complications
-
Thyroid Neoplasms / radiotherapy